Applied Genetic Technologies Corporation (NASDAQ: AGTC) was founded in 1999 and is headquartered in Alachua, Florida, USA, with 78 full-time employees. It is a clinical-stage biotechnology company that develops transformations for patients with rare and debilitating diseases. Gene therapy.
Applied Genetic Technologies Corporation (AGTC):
The main products of Applied Genetic Technologies include four ophthalmology development projects involving three goals, including:
1. X-linked retinoschisis, in phase I/II clinical trials;
2. X-linked retinitis pigmentosa (retinitis pigmentosa), in phase I/II clinical trials;
3. Achromatopsia, a phase I/II clinical trial for the treatment of hereditary retinal diseases, and preclinical procedures for adrenal leukodystrophy, which is a central nervous system and otological disease.
Applied Genetic Technologies Corporation has signed a cooperation agreement with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, Bionic Sight, LLC and the University of Florida Research Foundation.